LALPATHLAB1,912.00

Dr. Lal Path Labs Ltd.

· Pharma & Health
₹ CrorePeersMETROPOLISVIJAYATHYROCARENATCOPHARMNEULANDLABNHCOHANCESAILIFEMcap ₹32,045 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt83.30.00.00.0
Net Debt-391.4-619.3-665.4-665.4
Total Debt/Equity0.040.000.000.00
Net Debt/Equity-0.21-0.28-0.26-0.26
Total Debt/EBITDA0.140.000.000.00
Net Debt/EBITDA-0.64-0.89-0.85-0.79
Interest Coverage (EBIT/Interest)15.8424.8327.2227.22
Total Debt/Total Capital %4.230.000.000.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.